Ddeepull — Series C · €50M
Barcelona-based medtech deepull closed an oversubscribed €50 million Series C co-led by Columbus Venture Partners, Panakès Partners and Mérieux Equity Partners to fund clinical validation and regulatory approval of UllCORE, its automated system for detecting sepsis-causing pathogens directly from blood in about one hour. UllCORE received FDA Breakthrough Device Designation in December 2024; because three funds co-led, no single lead investor is reported.
LeadColumbus Venture Partners, Panakès Partners, Mérieux Equity Partners
RoundSeries C
Announced29 Apr 2025
CityBarcelona
SectorHealthtech & Bio · Medtech / Diagnostics
Source
G
M
G
M
The company
Investors 12
CColumbus Venture Partners
columbusvp.com
MMérieux Equity Partners
P
Panakès Partners
AAliath Bioventures
AAsabys Partners
asabys.com
A
Axis - ICO
www.axispart.com
Profile: AXIS
CCGHealth Ventures
G
Gesamo
IInnvierte (CDTI)
www.cdti.es
Profile: Centro para el Desarrollo Tecnológico y la Innovación
KKurma Partners
UUI Investissement
WWe Venture Capital
weventurecapital.com